ArticleClinical rheumatology2026
Association between body mass index and palindromic rheumatism risk and outcomes: a case-control study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimPalindromic rheumatism (PR) is a periodic rheumatic disease characterized by recurrent attacks of pain and swelling, affecting articular and periarticular structures. Despite the evidence supporting the association between overweight and obesity with autoimmune rheumatic diseases, the relation between body mass index (BMI) and PR remains underexplored. Therefore, this research aimed to evaluate the possible association between BMI and PR risk and outcomes.
methodsThis cross-sectional study utilized data from the CTDRC-PR Cohort. The PR group consisted of adults (age ≥ 18 years) diagnosed with PR according to the Guerne & Weisman criteria. Healthy controls (HCs) were selected from the general population enrolled in the Azar Cohort Study.
resultsOf the 229 patients followed in the CTDRC-PR cohort, 151 met the study inclusion criteria. Following 1:2 propensity score matching, the final analytical sample consisted of 147 PR patients and 294 matched HCs. No significant difference was observed in mean BMI between PR patients and HCs. In a multivariate logistic regression model adjusted for age, sex, marital status, and smoking status, BMI ≥ 25 kg/m
conclusionThe lack of association between BMI and PR risk or outcomes may reflect the unique immunological positioning of PR, which differs from classical autoimmune pathways sensitive to adiposity. It also underscores the limitations of BMI as a surrogate for metabolically active adipose tissue. Key Points • No significant difference was observed in mean BMI between PR patients and HCs. • In a multivariate logistic regression model adjusted for age, sex, marital status, and smoking status, neither overweight nor obesity was associated with an increased risk of PR.
Indexed as
Identifiers
41840172What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.